Syndros FDA Approval History
FDA Approved: Yes (First approved July 1, 2016)
Brand name: Syndros
Generic name: dronabinol
Dosage form: Oral Solution
Company: Benuvia Therapeutics Inc.
Treatment for: Anorexia, Nausea/Vomiting, Chemotherapy Induced
Syndros (dronabinol) is an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (THC) approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Development timeline for Syndros
| Date | Article |
|---|---|
| Jul 5, 2016 | Approval Insys Therapeutics Announces FDA Approval of Syndros (dronabinol) Oral Solution |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
